Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression
Sponsor: Eli Lilly and Company
A PHASE4 clinical study on Depression and Schizoaffective Disorder, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 6 data snapshots since 2001. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Sep 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anaheim, United States, Augusta, United States, Austin, United States, Buffalo, United States, Charlotte, United States, Chula Vista, United States, Clementon, United States, Denver, United States, El Paso, United States, Gaithersburg, United States and 20 more location s